Vaxart: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
 
CSV import
 
(2 intermediate revisions by the same user not shown)
Line 1: Line 1:
'''Vaxart''' is a biotechnology company that specializes in the development of oral recombinant vaccines. The company's proprietary technology platform is a novel approach to vaccine development, designed to allow for the oral administration of vaccines through a tablet, rather than by injection.
{{short description|American biotechnology company}}
{{Use mdy dates|date=October 2023}}


== History ==
[[File:Vaxart_Corporate_2022_Logo.png|thumb|right|Vaxart corporate logo]]
[[Vaxart]] was founded in 2004 with the goal of developing a new method of vaccine delivery that would improve the effectiveness and convenience of immunization. The company's initial focus was on the development of vaccines for influenza and norovirus, but it has since expanded its research and development efforts to include a range of other infectious diseases.
[[File:VaxartHQ.jpg|thumb|right|Vaxart headquarters]]


== Technology ==
'''Vaxart, Inc.''' is an American [[biotechnology]] company focused on developing oral [[vaccines]] administered by tablet rather than by injection. The company is headquartered in [[South San Francisco, California]].
Vaxart's technology platform is based on the use of recombinant [[adenovirus]] vectors to deliver vaccine antigens to the immune system. This approach allows for the oral administration of vaccines, which has several potential advantages over traditional injection-based methods. These include improved patient compliance, the ability to stimulate a broader immune response, and the potential for mass distribution in the event of a pandemic.


== Products ==
==History==
Vaxart's product pipeline includes vaccines for a number of infectious diseases, including [[influenza]], [[norovirus]], [[respiratory syncytial virus (RSV)]], and [[coronavirus disease 2019 (COVID-19)]]. The company's influenza vaccine has completed Phase 2 clinical trials, while its norovirus and RSV vaccines are in preclinical development. In 2020, Vaxart initiated a Phase 1 clinical trial for its oral COVID-19 vaccine.
Vaxart was founded in 2004 by Sean Tucker, who was a graduate student at the time. The company initially focused on developing vaccines for [[influenza]] and other respiratory viruses. In 2018, Vaxart became a publicly traded company through a reverse merger with Aviragen Therapeutics.


== Financials ==
==Technology==
As a publicly traded company, Vaxart's financial performance is closely watched by investors. The company's revenue is primarily derived from collaboration agreements, licensing fees, and government grants. In recent years, Vaxart has received significant funding from the [[Biomedical Advanced Research and Development Authority (BARDA)]] to support the development of its influenza and norovirus vaccines.
Vaxart's technology platform is based on the use of [[adenovirus]] vectors to deliver vaccine antigens in a tablet form. This approach aims to stimulate both systemic and mucosal immune responses, potentially offering advantages over traditional injectable vaccines. The oral delivery system is designed to be more convenient and accessible, especially in areas with limited healthcare infrastructure.


== See also ==
==Research and Development==
Vaxart has been involved in the development of vaccines for a variety of infectious diseases, including influenza, [[norovirus]], and [[coronavirus disease 2019|COVID-19]]. In 2020, the company announced that it was working on an oral COVID-19 vaccine candidate. The vaccine entered clinical trials, and Vaxart has been exploring partnerships to advance its development.
 
==COVID-19 Vaccine==
In response to the COVID-19 pandemic, Vaxart developed an oral vaccine candidate, VXA-CoV2-1. The vaccine is designed to be stable at room temperature, which could simplify distribution and administration. Early clinical trials have been conducted to assess its safety and immunogenicity.
 
==Partnerships and Collaborations==
Vaxart has collaborated with various organizations to advance its vaccine candidates. The company has received funding from the [[Biomedical Advanced Research and Development Authority]] (BARDA) and has partnered with other biotechnology firms to enhance its research capabilities.
 
==Controversies==
In 2020, Vaxart faced scrutiny over its claims of being selected for the U.S. government's Operation Warp Speed program. The company later clarified that it was not directly funded by the program but was involved in preliminary studies.
 
==Related pages==
* [[Biotechnology]]
* [[Vaccine]]
* [[Vaccine]]
* [[Biotechnology]]
* [[COVID-19 pandemic]]
* [[Clinical trial]]
* [[Infectious disease]]
 
== References ==
<references />


== External links ==
==References==
* [http://www.vaxart.com Official website]
{{reflist}}


[[Category:Biotechnology companies of the United States]]
[[Category:Biotechnology companies of the United States]]
[[Category:Pharmaceutical companies of the United States]]
[[Category:Companies listed on the Nasdaq]]
[[Category:2004 establishments in California]]
[[Category:Companies based in South San Francisco, California]]
[[Category:Companies based in South San Francisco, California]]
 
[[Category:Pharmaceutical companies established in 2004]]
{{biotech-company-stub}}
<gallery>
{{pharmacology-stub}}
File:Vaxart_Corporate_2022_Logo.png|Vaxart Corporate 2022 Logo
File:VaxartHQ.jpg|Vaxart Headquarters
</gallery>
<gallery>
File:Vaxart Corporate 2022 Logo.png|Vaxart Corporate 2022 Logo
File:VaxartHQ.jpg|Vaxart Headquarters
</gallery>

Latest revision as of 01:11, 20 February 2025

American biotechnology company



File:Vaxart Corporate 2022 Logo.png
Vaxart corporate logo
Vaxart headquarters

Vaxart, Inc. is an American biotechnology company focused on developing oral vaccines administered by tablet rather than by injection. The company is headquartered in South San Francisco, California.

History[edit]

Vaxart was founded in 2004 by Sean Tucker, who was a graduate student at the time. The company initially focused on developing vaccines for influenza and other respiratory viruses. In 2018, Vaxart became a publicly traded company through a reverse merger with Aviragen Therapeutics.

Technology[edit]

Vaxart's technology platform is based on the use of adenovirus vectors to deliver vaccine antigens in a tablet form. This approach aims to stimulate both systemic and mucosal immune responses, potentially offering advantages over traditional injectable vaccines. The oral delivery system is designed to be more convenient and accessible, especially in areas with limited healthcare infrastructure.

Research and Development[edit]

Vaxart has been involved in the development of vaccines for a variety of infectious diseases, including influenza, norovirus, and COVID-19. In 2020, the company announced that it was working on an oral COVID-19 vaccine candidate. The vaccine entered clinical trials, and Vaxart has been exploring partnerships to advance its development.

COVID-19 Vaccine[edit]

In response to the COVID-19 pandemic, Vaxart developed an oral vaccine candidate, VXA-CoV2-1. The vaccine is designed to be stable at room temperature, which could simplify distribution and administration. Early clinical trials have been conducted to assess its safety and immunogenicity.

Partnerships and Collaborations[edit]

Vaxart has collaborated with various organizations to advance its vaccine candidates. The company has received funding from the Biomedical Advanced Research and Development Authority (BARDA) and has partnered with other biotechnology firms to enhance its research capabilities.

Controversies[edit]

In 2020, Vaxart faced scrutiny over its claims of being selected for the U.S. government's Operation Warp Speed program. The company later clarified that it was not directly funded by the program but was involved in preliminary studies.

Related pages[edit]

References[edit]

<references group="" responsive="1"></references>

Retrieved from "https://wikimd.com/index.php?title=Vaxart&oldid=6332824"